Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 172 participants.
Also called NCT02291237
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 172 participants
- Sponsor
- Registry
-
NCT02291237 -
2013-004429-97
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, France, Germany, Israel, Italy, Netherlands, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT02291237. Randomized; quadruple masking; primary purpose treatment. Start 2015-02-05 (actual); primary completion 2017-01-20 (actual). Results posted on 2018-03-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
- Acronym
- LIBERTY-HCM
- Condition
- Hypertrophic Cardiomyopathy
- Intervention (Drug)
- Eleclazine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Gilead Sciences
Record details
- Record id
cardio:ct-nct02291237- Content hash
d1fa4bf12e7569524f00ea9909bdb6805f6a3a1a03b2b3d59242c9f49f62d5b5